Adaptive Biotechnologies and Collaborators to Present Data Demonstrating High-Throughput Sequencing for Minimal Residual Disease (MRD) is More Sensitive than Flow Cytometry and Can Be Used as a Determinant of Early Response to Therapy
Friday, June 10, 2016
SEATTLE, Wa., June 10, 2016 – Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, and collaborators will be presenting five studies demonstrating how Adaptive’s high-throughput sequencing platform enables diagnosis, detection and assessment of prognosis in hematological malignances and has increased sensitivity over flow cytometry. These data will be presented at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark, June 9-12, 2016.
Highlighted data include a study by Ilan Kirsch, MD (Adaptive Biotechnologies), et al., demonstrating the use of immunosequencing of peripheral blood from ALL patients to assess MRD in which bone marrow was hypocellular. In these patients, immunosequencing of peripheral blood was more sensitive than traditional flow cytometric analysis in the bone marrow. Another study by Dr. Kirsch, et al., demonstrated the use of high-throughput sequencing as a measure of early response to therapy in childhood Acute Lymphoblastic Leukemia (ALL). In this study, assessment of MRD using immunosequencing correlated with both outcome and event-free survival. A study by Dr. Hiroyuki Takamatsu (Kanazawa University), et al., compared the prognostic value of MRD using flow cytometry and immunosequencing on autografts of multiple myeloma patients, and revealed that patients who were MRD negative by immunosequencing tended to have better progression-free survival.
“These data further demonstrate the breadth of our immunosequencing technology’s applicability in hematological malignancies and the potential to provide precise results using non-invasive sampling procedures,” said Harlan Robins, Chief Scientific Officer and Co-Founder of Adaptive Biotechnologies. “Providing an ultra-sensitive, standardized method for detection, diagnosis and prognosis for people with lymphoid cancers may also help improve patient outcomes.”
Representatives from Adaptive Biotechnologies will be exhibiting at EHA booth #C4.210 to answer questions about its immunosequencing technology.
Abstract #S101: Improved Efficacy after Incorporating Autologous Stem Cell Transplant (ASCT) into KRD Treatment with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) in Newly Diagnosed Multiple Myeloma
Presenter: Dr. Andrzej Jakubowiak
Date/Time: June 10, 11:45-12; Hall A1
Abstract #S496: High Throughput Sequencing as a Measure of Early Response to Therapy in Childhood ALL
Presenter: Dr. Ilan Kirsch
Date/Time: June 11, 16-16:15; Auditorium 2
Abstract #E854: Molecular Detection of ALL in the Peripheral Blood is More Sensitive than Flow Cytometric Analysis of the Bone Marrow in Patients with Treatment-Related Hypocellularity
Author: Takamatsu, et al.
Abstract #E1293: Comparison between 8-Color Multiparameter Flow Cytometry and Next-Generation Sequencing to Detect Minimal Residual Disease in Multiple Myeloma Patients who Underwent Auto-SCT
Author: Kirsch, et al.
Abstract #E1148: High Throughput TCR Sequencing Provides Added Value in the Diagnosis of Cutaneous T-cell Lymphoma
Author: Kirsch, et al.
About Adaptive Biotechnologies®
Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. For more information please visit adaptivebiotech.com.